Viskase Holdings, Inc.

VISK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Revenue $6.9M $8.4M $8.4M $17.5M $31.2M $34.5M $42.6M $48.1M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $0 $2.7M $20.9M $40.2M
SG&A Expense
Operating Income $5.9M $7.0M $6.6M $10.8M $28.8M $18.2M $-4.0M $-16.5M
Operating Margin 84.6% 83.6% 79.3% 61.9% 92.4% 52.6% -9.3% -34.2%
Interest Expense $0 $2.1M $5.3M $5.9M
Pretax Income $5.9M $7.0M $6.6M $10.8M $28.9M $18.1M $-6.9M $-20.6M
Income Tax Expense $6.0K $1.6M $7.8M $-10.8M $56.0K $-28.0K $-4.1M $205.0K
Net Income $5.8M $5.4M $-1.1M $21.6M $28.8M $18.2M $-2.8M $-20.8M
Net Margin 84.5% 65.0% -13.4% 124.0% 92.4% 52.6% -6.5% -43.2%
EPS (Basic) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
EPS (Diluted) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Shares Outstanding (Basic) 44.21B 44.22B 44.22B 44.20B 44.13B 43.78B 46.74B 51.91B
Shares Outstanding (Diluted) 44.21B 44.22B 44.22B 44.22B 44.25B 51.05B 46.74B 51.91B
Dividends Per Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
← Newer Page 2 of 3 Older →